Last updated 2 months ago
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
1020 patients around the world
Available in Spain, United States, Belgium, Argentina
Pfizer
1Research sites
1020Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor.Documented HER2-negative tumor.Previously untreated with any systemic anticancer therapy for their locally advanced or metastatic disease.Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1.
- In visceral crisis at risk of immediately life-threatening complications in the short term.Current or past history of central nervous system metastases.Have received prior (neo)adjuvant endocrine therapy (ET) and had recurrence during or within 12 months after the last dose of ET.Have received prior (neo)adjuvant CDK4/6i and had recurrence during or within 12 months after the last dose of CDK4/6i.Inadequate renal function, hepatic dysfunction, or hematologic abnormalities.
Sites
Organización Médica de Investigación (OMI)
Recruiting
StudyFourLight-3
SponsorPfizer
Study typeInterventional
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06760637
